Vivaxin, a Brazilian vaccine developed to combat Plasmodium vivax, the parasite responsible for 82.5% of malaria cases in Brazil, had its patent application filed in October 2023.
Key information about Vivaxin
- Brazilian context: Vaccines available globally are ineffective against Plasmodium vivax, the predominant parasite in Brazil. Vivaxin fills this gap by offering an approach targeted to local needs.
- Advances in development: After promising results in the preclinical phase, which included testing on animals, the request for authorization for clinical studies in humans will be submitted to Anvisa by January.
- Protection via intellectual property: The patent application covers the production process and formulation of the vaccine, including the adjuvant developed by the researchers. This protection is essential to guarantee exclusivity and enable future partnerships.
- Strategic partnership: The collaboration between University of the São Paulo (USP) and the University of Minas Gerais (UFMG) sought to overcome a critical stage between academic research and practical application and create a fully national product.
Malaria remains a major public health challenge, particularly in Brazil’s Amazon region, which accounted for 99.98% of cases in 2023. With 139,884 reported diagnoses last year, innovative solutions like Vivaxin are urgently needed.
The Role of Intellectual Property in Biotechnology
Patent filings are a strategic step in establishing Brazil as a key player in vaccine and health technology development. Monitoring initiatives like Vivaxin is essential to identify opportunities and support scientific advancements in the region.
Contact Tavares IP to learn how we can assist in protecting and enhancing your innovations in Brazil and globally.
Source: Época
